Five notes:
1. Despite surgical challenges in the first quarter, Mr. Gorsky said he was “encouraged” by hospitals’ ability to navigate current patient demands. Overall, hospital volumes are decreasing no more than 10-15 percent, particularly in the U.K. and parts of Europe, he said.
2. Johnson & Johnson plans to use 2019 as “more of a benchmark” for financial performance in 2021, Mr. Gorsky said.
3. The company’s fourth-quarter revenue of $6.6 billion was $59 million short of Wall Street expectations, according to MedTech Dive. Analysts reported that orthopedics revenue missed projections by $92 million, with further misses for hips ($12 million), knees ($38 million), and spine and other ($56 million).
4. This month, Johnson & Johnson received FDA clearance for its Velys robotic-assisted solutions. The system will complement its Attune system for knee replacement, with applications for hip procedures in the pipeline.
5. Mr. Gorsky said the industry is “just starting to unlock the full potential and benefits of robotic and digital technologies,” and believes Johnson & Johnson is well-positioned to bring these innovations “to the surgery suite over the next 10, 20, and 30 years.”
More articles on devices:
Spine surgeon, inventor files patent infringement suit against NuVasive
14 key thoughts on bundled payments in spine surgery
Texas orthopedic supergroup launches with 154 physicians, eyes future growth
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.